XYLOCAINE 1.5% W/ DEXTROSE 7.5% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xylocaine 1.5% W/ Dextrose 7.5%, and when can generic versions of Xylocaine 1.5% W/ Dextrose 7.5% launch?
Xylocaine 1.5% W/ Dextrose 7.5% is a drug marketed by Fresenius Kabi Usa and is included in one NDA.
The generic ingredient in XYLOCAINE 1.5% W/ DEXTROSE 7.5% is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xylocaine 1.5% W/ Dextrose 7.5%
A generic version of XYLOCAINE 1.5% W/ DEXTROSE 7.5% was approved as lidocaine hydrochloride by WOCKHARDT BIO AG on November 18th, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XYLOCAINE 1.5% W/ DEXTROSE 7.5%?
- What are the global sales for XYLOCAINE 1.5% W/ DEXTROSE 7.5%?
- What is Average Wholesale Price for XYLOCAINE 1.5% W/ DEXTROSE 7.5%?
Summary for XYLOCAINE 1.5% W/ DEXTROSE 7.5%
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Clinical Trials: | 159 |
Formulation / Manufacturing: | see details |
DailyMed Link: | XYLOCAINE 1.5% W/ DEXTROSE 7.5% at DailyMed |
![XYLOCAINE 1.5% W/ DEXTROSE 7.5% drug patent expirations Drug patent expirations by year for XYLOCAINE 1.5% W/ DEXTROSE 7.5%](/p/graph/s/t/XYLOCAINE_1.5%_W/_DEXTROSE_7.5%-patent-expirations.png)
Recent Clinical Trials for XYLOCAINE 1.5% W/ DEXTROSE 7.5%
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
CHU de Reims | N/A |
Vrije Universiteit Brussel | Phase 4 |
Centre hospitalier de l'Université de Montréal (CHUM) | Phase 4 |
US Patents and Regulatory Information for XYLOCAINE 1.5% W/ DEXTROSE 7.5%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | XYLOCAINE 1.5% W/ DEXTROSE 7.5% | lidocaine hydrochloride | INJECTABLE;SPINAL | 016297-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |